Toogood PL - Search Results

1

Synthesis of (-)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates.

Ruble JC, Hurd AR, Johnson TA, Sherry DA, Barbachyn MR, Toogood PL, Bundy GL, Graber DR, Kamilar GM. Ruble JC, et al. Among authors: toogood pl. J Am Chem Soc. 2009 Mar 25;131(11):3991-7. doi: 10.1021/ja808014h. J Am Chem Soc. 2009. PMID: 19260642

2

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW. Toogood PL, et al. J Med Chem. 2005 Apr 7;48(7):2388-406. doi: 10.1021/jm049354h. J Med Chem. 2005. PMID: 15801831

3

Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer.

Aicher TD, Van Huis CA, Hurd AR, Skalitzky DJ, Taylor CB, Beleh OM, Glick G, Toogood PL, Yang B, Zheng T, Huo C, Gao J, Qiao C, Tian X, Zhang J, Demock K, Hao LY, Lesch CA, Morgan RW, Moisan J, Wang Y, Scatina J, Paulos CM, Zou W, Carter LL, Hu X. Aicher TD, et al. Among authors: toogood pl. J Med Chem. 2021 Sep 23;64(18):13410-13428. doi: 10.1021/acs.jmedchem.1c00731. Epub 2021 Sep 9. J Med Chem. 2021. PMID: 34499493

4

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.

Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, Morgan RW, Zawidzka EM, Mertz D, Bousley D, Majchrzak K, Kryczek I, Taylor C, Van Huis C, Skalitzky D, Hurd A, Aicher TD, Toogood PL, Glick GD, Paulos CM, Zou W, Carter LL. Hu X, et al. Among authors: toogood pl. Oncoimmunology. 2016 Nov 4;5(12):e1254854. doi: 10.1080/2162402X.2016.1254854. eCollection 2016. Oncoimmunology. 2016. PMID: 28123897 Free PMC article.

5

A short and efficient synthesis of L-5,5,5,5',5',5'-hexafluoroleucine from N-Cbz-L-serine.

Anderson JT, Toogood PL, Marsh EN. Anderson JT, et al. Among authors: toogood pl. Org Lett. 2002 Nov 28;4(24):4281-3. doi: 10.1021/ol026922j. Org Lett. 2002. PMID: 12443078

6

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J 3rd, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL. VanderWel SN, et al. Among authors: toogood pl. J Med Chem. 2005 Apr 7;48(7):2371-87. doi: 10.1021/jm049355+. J Med Chem. 2005. PMID: 15801830

7

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

Bathini Y, Singh I, Harvey PJ, Keller PR, Singh R, Micetich RG, Fry DW, Dobrusin EM, Toogood PL. Bathini Y, et al. Among authors: toogood pl. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3881-5. doi: 10.1016/j.bmcl.2005.05.131. Bioorg Med Chem Lett. 2005. PMID: 15993068

8

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Fry DW, et al. Among authors: toogood pl. Mol Cancer Ther. 2004 Nov;3(11):1427-38. Mol Cancer Ther. 2004. PMID: 15542782

9

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D, Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E. Barvian M, et al. J Med Chem. 2000 Nov 30;43(24):4606-16. doi: 10.1021/jm000271k. J Med Chem. 2000. PMID: 11101352

10

Cyclin-dependent kinase inhibitors for treating cancer.

Toogood PL. Toogood PL. Med Res Rev. 2001 Nov;21(6):487-98. doi: 10.1002/med.1021. Med Res Rev. 2001. PMID: 11607930 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters